Plus, more news from Amicus Therapeutics, Mogrify, and Clade Therapeutics.
Rocket gets a March date with FDA: The FDA has until March 31 to decide whether to approve Rocket Pharmaceuticals’ gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), which is a rare white blood cell disorder that can result in severe infections. Life expectancy is short, and some babies do not survive past infancy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.